An investigation of a possible relationship between olfactory identification deficits at first episode and four-year outcomes in patients with psychosis

Kimberley P. Good, Philip Tibbo, Heather Milliken, David Whitehorn, Maria Alexiadis, Nancy Robertson, Lili C. Kopala

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

25 Citas (Scopus)

Resumen

Objective: Olfactory identification deficits are found in a significant proportion of patients with schizophrenia spectrum psychotic disorders and appear to be predictive of incomplete remission of negative and cognitive symptoms. In the current study, we examined whether patients with first episode psychosis who have olfactory identification deficits (microsmic) have poorer functional outcome than those whose olfactory status is normal (normosmic). Method: Sixty-six (66) first episode psychosis patients (46 M and 20 F) were assessed with the University of Pennsylvania Smell Identification Test (UPSIT) at baseline. UPSIT scores served to classify patients into subgroups. The patients' psychiatrists completed the Social and Occupational Functioning Assessment Scale (SOFAS) and the Levels of Functioning Scale (LOFS) after at least 6 months of treatment. The Premorbid Assessment Scale (PAS) was rated by a parent at baseline. Results: Thirty-eight percent (38%) of the sample was identified as 'microsmic'. LOFS and SOFAS scores were significantly lower in the microsmic group than in the normosmic group. Symptoms were significantly worse in the microsmic group in comparison to the normosmic group. PAS scores did not differ between groups. Conclusions: First episode patients identified as microsmic at baseline assessment went on to demonstrate poorer functional outcome compared to normosmic patients despite no differences in premorbid adjustment. Olfactory identification deficits at first episode may provide a marker for poorer outcome. Testing olfaction is simple and inexpensive, and could provide clinically valuable information at first episode to identify those patients who might benefit from more intensive interventions promoting functional recovery.

Idioma originalEnglish
Páginas (desde-hasta)60-65
Número de páginas6
PublicaciónSchizophrenia Research
Volumen124
N.º1-3
DOI
EstadoPublished - dic. 2010

Nota bibliográfica

Funding Information:
Dr. H. Milliken has received funding for unrelated projects including industry sponsored clinical trials, advisory boards and CME honoraria from Eli Lilly Canada, Janssen Ortho, Pfizer, and Sanofi-Aventis.

Funding Information:
Funding for this study was provided, in part, by the Canadian Institutes for Health Research/Nova Scotia Health Research Fund (Grant # ROP-74171), NARSAD, Department of Psychiatry Research Fund, Schizophrenia Society of Canada. The funding agencies had no further role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.

Funding Information:
Dr. K. Good reports unrelated research grant support from Pfizer Canada, Pfizer Inc. and Janssen Research Foundation.

ASJC Scopus Subject Areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Huella

Profundice en los temas de investigación de 'An investigation of a possible relationship between olfactory identification deficits at first episode and four-year outcomes in patients with psychosis'. En conjunto forman una huella única.

Citar esto